Fate Therapeutics FATE
NASDAQ FATE
$2.38 +0.00 (+0.00%)
At close: Sep 29, 2026 · 4:00 PM EDT

Fate Therapeutics (FATE) Convertible Debt (2013)

Updated

Fate Therapeutics (FATE) reported Convertible Debt of $23.7 million for Q3 2013.

Analysis

Fate Therapeutics (FATE) Convertible Debt (2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Fate Therapeutics 277.73 Mn 277.73 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2013 23.70 Mn
API Access

Fate Therapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=FATE&period=max&api_key=YOUR_API_KEY